Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)

NCT05446298 is registered in ClinicalTrials.gov with OncoC4, Inc. as lead sponsor.

NCT NCT05446298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05446298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)
Lead sponsor
OncoC4, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 22, 2022
Completion date
August 30, 2027
Enrollment
58 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, high grade serous adenocarcinoma of ovary, ovarian cancer, primary peritoneal carcinoma